Compositions and methods for treatment of skin infections

Abstract

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

1 - 84 . (canceled) 
     
     
         85 . A method for treating a skin infection comprising administering to a subject having said skin infection, a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising:
 a. at least about 15 weight % of a keratolytic agent;   b. about 10 weight % to about 20 weight % of a molecule comprising a pyruvate group; and   c. about 1 or less weight % of a halogen containing moiety.   
     
     
         86 . The method of  claim 85 , wherein said keratolytic agent is salicylic acid, pyruvic acid, chloroacetic acid, trichloroacetic acid, menthol, acetic acid, ascorbic acid, pantothenic acid, lactic acid, a salt of any of the above, or any combination thereof. 
     
     
         87 . The method of  claim 85 , wherein said keratolytic agent is salicylic acid, ester thereof, salt thereof, or any combination thereof. 
     
     
         88 . The method of  claim 87 , wherein said pharmaceutical composition comprises about 17 weight % of said keratolytic agent. 
     
     
         89 . The method of  claim 85 , wherein said pharmaceutical composition further comprises an excipient, wherein said excipient comprises butylated hydroxy toluene. 
     
     
         90 . The method of  claim 88 , wherein said molecule comprising said pyruvate group is ethyl pyruvate. 
     
     
         91 . The method of  claim 90 , wherein said pharmaceutical composition comprises about 15 weight % ethyl pyruvate. 
     
     
         92 . The method of  claim 91 , wherein said halogen containing moiety comprises iodine. 
     
     
         93 . The method of  claim 92 , wherein said halogen containing moiety is polyvinylpyrrolidone-iodine. 
     
     
         94 . The method of  claim 93 , wherein said pharmaceutical composition comprises about 0.5 weight % polyvinylpyrrolidone-iodine. 
     
     
         95 . The method of  claim 85 , wherein said pharmaceutical composition further comprises a thickening agent. 
     
     
         96 . The method of  claim 95 , wherein said thickening agent comprises polyethylene glycol, poly acrylic acid, vegetable gums, petroleum jelly, guar gum, sodium chloride, nitrocellulose, hydroxypropyl cellulose, or any combination thereof. 
     
     
         97 . The method of  claim 85 , wherein said skin infection is caused by a virus. 
     
     
         98 . The method of  claim 97 , wherein said virus is herpes simplex virus, human papillomavirus, herpes zoster, molluscum contagiosum virus, human herpesvirus-3, or varicella. 
     
     
         99 . The method of  claim 98 , wherein said virus is said human papillomavirus. 
     
     
         100 . The method of  claim 98 , wherein said virus is said molluscum contagiosum virus. 
     
     
         101 . The method of  claim 97 , wherein said skin infection is squamous cell papilloma. 
     
     
         102 . The method of  claim 85 , wherein said skin infection is a wart. 
     
     
         103 . The method of  claim 85 , wherein said skin infection is rosacea. 
     
     
         104 . The method of  claim 85 , wherein said pharmaceutical composition does not comprise 5-fluorouracil, dinitrochlorobenzene, bleomycin or cantharidin.